Amygdala Neuroscience

company

About

Amygdala Neuroscience is a free online portal to create group projects and media item related to neuroscience.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$5.60M
Industries
Biotechnology,Health Care,Neuroscience,Online Portals,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse.

In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies.

Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$6.95M
Amygdala Neuroscience has raised a total of $6.95M in funding over 2 rounds. Their latest funding was raised on Nov 18, 2019 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 18, 2019 Series A $5.60M 1 National Institutes of Health Detail
Oct 21, 2019 Grant $1.35M 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Amygdala Neuroscience is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Series A